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Abstract
Sarcomatoid renal cell carcinoma represents high-grade transformation of different subtypes of
renal cell carcinoma and is associated with a dismal prognosis and high resistance to chemotherapy.
We report on the course of disease of a 63 years old patient undergoing a nearly complete
remission of multiple intracranial and spinal metastatic lesions of a sarcomatoid renal cell carcinoma
by a combined chemotherapy with temozolomide and pegylated liposomal doxorubicin.
Case presentation
In December 2004, a 63-year-old female, Caucasian
patient presented in our hospital with progressive para-
plegia due to multiple CNS metastasis of renal cell carci-
noma (RCC). Already in January 2003, she had noticed a
slowly progressive numbness of her right forearm and
belt-shaped pain of her chest due to metastatic disease at
the level of T1/2 causing compression of the spinal cord.
Both, the RCC and the metastatic lesion were completely
removed in February 2003. Pathological analysis of the
renal cell tumor revealed a clear cell RCC, the intraspinal
metastasis was characterized by mesenchymal appearance
with epithelial components and areas with spindle cells.
Based on the histological findings, the National Reference
Center of Neuropathology made the diagnosis of an
undifferentiated sarcoma – most likely a sarcomatoid
metastasis of the clear cell RCC.
Spinal surgery was followed by local radiotherapy (cervi-
cal and upper thoracic spine, 50 Gy; primary tumor site:
59.4 Gy) and chemotherapy with temozolomide (three
cycles, 1600 mg per cycle). After one year, MRI revealed
multiple asymptomatic relapses affecting the clivus, C6,
and T11-S1. Another local radiotherapy (Clivus-C6 and
T11-S2, 50 Gy) was administered until July 2004. In July
2004, the patient noted for the first time progressive prick-
ling dysesthesias due to a new recurrence affecting T5-10.
The patient then started palliative chemotherapy with tha-
lidomide (200 mg orally every day).
Until December 2004, the patient further deteriorated
and was finally unable to stand when presenting in our
hospital. MRI showed a marked progression of all meta-
static lesions in the CNS (Figure 1). We initiated chemo-
therapy with temozolomide orally (200 mg/m2) on five
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consecutive days every four weeks and pegylated lipo-
somal doxorubicin intravenously (20 mg/m2 every two
weeks). In addition, we treated the patient with methyl-
prednisolone, glycerine, and thalidomide. The patient's
clinical condition improved rapidly and four weeks later,
she was able to climb four storeys with her walking frame.
In January 2005, MRI showed a nearly complete remis-
sion of the intracranial metastases and a partial remission
of the spinal lumps (Figure 2). The patient received the
first cycle of chemotherapy regularly. Then, prolonged
myelosuppression required dose reduction and finally the
discontinuation of the chemotherapy before finishing the
second cycle. In addition, the port for chemotherapy got
infected and multiple septic abscesses occurred. After dis-
continuation of chemotherapy in March 2005 the symp-
toms reocurred due to regrowth of the metastases. As signs
December 2004: Contrast-enhanced axial (A, B), sagittal (C),  and coronal (D) T1-weighted MR-images of the brain and  sagittal T1- and T2-weighted MR-images (E, F) of the spine  showing multiple intracranial metastatic nodules and exten- sive spinal involvement Figure 1
December 2004: Contrast-enhanced axial (A, B), sagittal 
(C), and coronal (D) T1-weighted MR-images of the brain 
and sagittal T1- and T2-weighted MR-images (E, F) of the 
spine showing multiple intracranial metastatic nodules and 
extensive spinal involvement.
January 2005: Contrast-enhanced axial (A, B), sagittal (C),  and coronal (D) T1-weighted MR-images of the brain and  sagittal T1-weighted MR-image (E) of the spine demonstrat- ing significant regression of the tumor Figure 2
January 2005: Contrast-enhanced axial (A, B), sagittal (C), 
and coronal (D) T1-weighted MR-images of the brain and 
sagittal T1-weighted MR-image (E) of the spine demonstrat-
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of inflammation still reoccurred intermittently, we were
not able to restart chemotherapy. The patient was dis-
charged and died in June 2005 due to progressive disease.
Discussion
Sarcomatoid RCC is not a distinct entity but represents a
common histological phenotype after high-grade trans-
formation of different subtypes of RCC [1]. It is associated
with a dismal prognosis with tumors metastasizing earlier
[1,2]. RCC are usually resistant to classical chemothera-
peutic agents but there are several small case studies
reporting on partial remissions of sarcomatoid RCC after
doxorubicin-based chemotherapeutic protocols [3-7]. The
rationale for combining temozolomide and pegylated
liposomal doxorubicin was based on their anti-tumor
activity, their good penetration of the blood-brain barrier,
and no significant overlapping toxicities. The combined
therapy usually is well tolerated [8,9] and severe adverse
events as seen in our patient are uncommon. To our
knowledge, this is the first report on the effective treat-
ment of multiple CNS metastasis of a sarcomatoid RCC
with temozolomide and pegylated liposomal doxorubicin
suggesting that the combination is treatment option for
recurrent CNS metastasis of sarcomatoid RCC.
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